An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibitors

Estado	Tipo de Participantes	Rangos de Edad
Reclutando	Sujetos incapaces de otorgar consentimiento	Menores de 18 , Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Hombres	Fase IV	101
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	Si	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	profilaxis, tratamiento, seguridad, eficacia, farmacocinética, farmacogenética, farmacoeconómica	NO

Información

Identificador
2024-516741-39-00 (CTIS)

Cod. Protocolo
MOTIVATE

Transicionado 2019-003427-38

Área terapéutica
Enfermedades [C] - Hematología [C15]|

Enfermedad investigada
Haemophilia A

Título Científico
MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A An International Low-Interventional Pragmatic

Investigator Initiated Trial

Justificación

No aportado

Objetivo Principal

The primary objective for Groups 1 and 2 is to evaluate ITI outcomes as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 Bethesda units (BU)/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% international units (IU)/kg body weight (BW) 3. FVIII half-life 6 h The primary objective for Group 3 is to evaluate the annualised bleeding rate (ABR) compared with the ABR in Group 1 and Group 2.

Variables de Evaluación Primaria

The primary endpoint in Group 1 and Group 2 is to evaluate ITI outcome as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% IU/kg BW 3. FVIII half-life 6 h The primary endpoint for Group 3 is to evaluate the ABR compared with the ABR in Group 1 and Group 2.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Secondary objectives for participants in Group 1 and Group 2 include: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success Secondary objectives for all 3 groups include the assessment of: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks) 2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures 4.Proportion of participants experiencing adverse drug reactions (ADRs) against haemophilia treatment 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Variables de Evaluación Secundaria

For participants in Group 1 and Group 2: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success
For participants in all 3 groups: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks)

2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures
For participants in all 3 groups: 4.Proportion of participants experiencing ADRs 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1.Participants can be of any age at the time of enrolment into the trial. 2.Male persons with hemophilia A (HA), of any severity, who have a historical inhibitor titre 0.6 BU/mL, including those who have failed previous ITI attempt(s) 3.Persons undergoing ITI with Nuwiq®, octanate® or wilate® or undergoing ITI with Nuwiq®, octanate® or wilate® and receiving prophylactic therapy with emicizumab, aPCC or rFVIIa 4.Participants or participants parent(s)/legal guardian(s) must be capable of giving signed informed consent and be able to understand the trial documents

Criterios de Exclusión

1.Participants are excluded from the trial if any coagulation disorder other than HA is diagnosed 2.Partly retrospective patients will be excluded if detailed documentation on treatment, all BEs, inhibitor titres and FVIII levels is not available for the retrospective period

Calendario

(Última actualización: 22/10/2025)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
09/12/2020	27/04/2021	12/05/2021	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
No aportado	No aportado	No aportado	No aportado	No aportado

Promotor

HZRM Haemophilie-Zentrum Rhein Main GmbH Germany

Stresemannallee 15Sachsenhausen

Contact Person

Carmen Escuriola

+14047851112

carmen.escuriola@hzrm.de

Monetary support: N/A

Tipo de promotor: No comercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Centros

No iniciado (--/--/----)

Hospital General Universitario Dr. Balmis

Alicante

ALICANTE

Dept of Haemostasis and Thrombosis

Activo (27/04/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Servicio de Hematología y Hemoterapia

No iniciado (--/--/----)

Hospital Universitario San Juan De Alicante

Sant Joan D'alacant

ALICANTE

Hematology Department

No iniciado (09/12/2020)

Hospital Universitario Virgen Del Rocio

Sevilla

SEVILLA

Servicio de Hematología y Hemoterapia

Medicamentos

FEIBA 500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Principios Activos: N/A

Experimental

CEVENFACTA 5 mg (225 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 250 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

OCTANATE 250 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 2500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Wilate 500, 500 I.E. VWF/500 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Principios Activos: N/A

Experimental

NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Experimental

NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 1500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

Wilate 1000, 1000 I.E. VWF/1000 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Principios Activos: N/A

Experimental

Nuwiq 2000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 1000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

OCTANATE 1000 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

[redacted]

Código ATC: B02BX06 - EMICIZUMAB
Principios Activos: N/A

Experimental

[redacted]

SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION
Principios Activos: N/A

Experimental

[redacted]

Nuwiq 3000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION
Principios Activos: N/A

Experimental

[redacted]

CEVENFACTA 2 mg (90 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION
Principios Activos: N/A

Experimental

[redacted]

CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION
Principios Activos: N/A

Experimental

[redacted]

Hemlibra 150 mg/mL solution for injection

SUSPENSION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB
Principios Activos: N/A

Experimental

[redacted]

FEIBA 1000 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

SOLUTION FOR INFUSION
INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII
Principios Activos: N/A

Experimental

[redacted]

Nuwiq 500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION
Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB
Principios Activos: N/A

Experimental

Nuwiq 4000 IU powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION
Principios Activos: N/A

Experimental

OCTANATE 500 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION
Principios Activos: N/A

Experimental

NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION
Principios Activos: N/A

Experimental

Hemlibra 30 mg/mL solution for injection
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB
Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB
Principios Activos: N/A

Experimental

FEIBA 2500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.
SOLUTION FOR INFUSION
INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII
Principios Activos: N/A

Experimental

Sin resultados

An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibitors

State	Type of participants	Age Ranges
Recruiting	Incapable subjects of giving consent	Less than 18 , Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Men	Phase IV	101
Results	**Low level of intervention**	**Rare disease**
No results	Yes	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	prophylaxis, treatment, safety, effectiveness, pharmacokinetics, pharmacogenetics, pharmacoeconomic	NO

Information

Identifier
2024-516741-39-00 (CTIS)

Protocol Code
MOTIVATE

Transitioned 2019-003427-38

Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]|

Investigated Disease
Haemophilia A

Scientific Title
MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A An International Low-Interventional Pragmatic

Investigator Initiated Trial

Rationale

Not provided

Main Objective

The primary objective for Groups 1 and 2 is to evaluate ITI outcomes as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 Bethesda units (BU)/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% international units (IU)/kg body weight (BW) 3. FVIII half-life 6 h The primary objective for Group 3 is to evaluate the annualised bleeding rate (ABR) compared with the ABR in Group 1 and Group 2.

Primary Endpoints

The primary endpoint in Group 1 and Group 2 is to evaluate ITI outcome as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% IU/kg BW 3. FVIII half-life 6 h The primary endpoint for Group 3 is to evaluate the ABR compared with the ABR in Group 1 and Group 2.

Temporary moments of secondary assessment

Not provided

Secondary Objective

Secondary objectives for participants in Group 1 and Group 2 include: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success Secondary objectives for all 3 groups include the assessment of: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks) 2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures 4.Proportion of participants experiencing adverse drug reactions (ADRs) against haemophilia treatment 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Secondary Endpoints

For participants in Group 1 and Group 2: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success
For participants in all 3 groups: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks)

2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures
For participants in all 3 groups: 4.Proportion of participants experiencing ADRs 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1.Participants can be of any age at the time of enrolment into the trial. 2.Male persons with hemophilia A (HA), of any severity, who have a historical inhibitor titre 0.6 BU/mL, including those who have failed previous ITI attempt(s) 3.Persons undergoing ITI with Nuwiq®, octanate® or wilate® or undergoing ITI with Nuwiq®, octanate® or wilate® and receiving prophylactic therapy with emicizumab, aPCC or rFVIIa 4.Participants or participants parent(s)/legal guardian(s) must be capable of giving signed informed consent and be able to understand the trial documents

Exclusion criteria

1.Participants are excluded from the trial if any coagulation disorder other than HA is diagnosed 2.Partly retrospective patients will be excluded if detailed documentation on treatment, all BEs, inhibitor titres and FVIII levels is not available for the retrospective period

Calendar

(Last Update: 22/10/2025)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
09/12/2020	27/04/2021	12/05/2021	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

HZRM Haemophilie-Zentrum Rhein Main GmbH Germany

Stresemannallee 15Sachsenhausen

Contact Person

Carmen Escuriola

+14047851112

carmen.escuriola@hzrm.de

Monetary support: N/A

Sponsor type: No commercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Sites

not initialized (--/--/----)

Hospital General Universitario Dr. Balmis

Alicante

ALICANTE

Dept of Haemostasis and Thrombosis

Active (27/04/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Servicio de Hematología y Hemoterapia

not initialized (--/--/----)

Hospital Universitario San Juan De Alicante

Sant Joan D'alacant

ALICANTE

Hematology Department

not initialized (09/12/2020)

Hospital Universitario Virgen Del Rocio

Sevilla

SEVILLA

Servicio de Hematología y Hemoterapia

Medication

FEIBA 500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Active Principles: N/A

Experimental

CEVENFACTA 5 mg (225 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 250 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

OCTANATE 250 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 2500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Wilate 500, 500 I.E. VWF/500 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Active Principles: N/A

Experimental

NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Experimental

NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 1500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Wilate 1000, 1000 I.E. VWF/1000 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Active Principles: N/A

Experimental

Nuwiq 2000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 1000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

OCTANATE 1000 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

ATC code: B02BX06 - EMICIZUMAB
Active Principles: N/A
Experimental

SOLUTION FOR INJECTION
INTRAVENOUS
ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION
Active Principles: N/A
Experimental

Nuwiq 3000 IU powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS
ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION
Active Principles: N/A
Experimental

CEVENFACTA 2 mg (90 KIU) powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS
ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION
Active Principles: N/A
Experimental

CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS
ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION
Active Principles: N/A
Experimental

Hemlibra 150 mg/mL solution for injection
SUSPENSION FOR INJECTION
SUBCUTANEOUS USE
ATC code: B02BX06 - EMICIZUMAB
Active Principles: N/A
Experimental

FEIBA 1000 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
SOLUTION FOR INFUSION
INTRAVENOUS
ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII
Active Principles: N/A
Experimental

Nuwiq 500 IU powder and solvent for solution for injection
SOLUTION FOR INJECTION
INTRAVENOUS
ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION
Active Principles: N/A
Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Nuwiq 4000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

OCTANATE 500 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

FEIBA 2500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Active Principles: N/A

Experimental

No results